Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody

(2011) Joyce Varughese et al.   CANCER

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients

(2010) Eliana Bignotti et al.   EUROPEAN JOURNAL OF CANCER

Ovarian and Uterine Carcinosarcomas

(2010) Gunjal Garg et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway

(2010) Rafael Cubas et al.   Molecular Cancer

Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

(2010) Chien-Hsing Chang et al.   MOLECULAR CANCER THERAPEUTICS

Carcinosarcoma of the Ovary

(2009) Leigh A. Cantrell et al.   OBSTETRICAL & GYNECOLOGICAL SURVEY

A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer

(2008) E. Guerra et al.   CANCER RESEARCH

Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers

(2008) J. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Molecular genetic aberrations of ovarian and uterine carcinosarcomas—a CGH and FISH study

(2008) Alexander Schipf et al.   VIRCHOWS ARCHIV